Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer
Tongchen He(Central South University), Arul M. Chinnaiyan(University of Michigan), Jasmine P. Wisniewski(University of Michigan), Hanbyul Cho(University of Michigan), Bailey W. Jackson(University of Michigan), Somnath Mahapatra(University of Michigan), Chandrasekhar Abbineni(Aurigene Discovery Technologies (India)), Yu‐Sun Chang(Chang Gung University of Science and Technology), Xuhong Cao(Howard Hughes Medical Institute), Siyu Hou(University of Michigan), Sandeep Dukare(Aurigene Discovery Technologies (India)), Abhijit Parolia, Kiran Aithal(Aurigene Discovery Technologies (India)), Samiulla D.S(Aurigene Discovery Technologies (India)), Rahul Mannan(University of Michigan), Eleanor Young(University of Michigan), Stephanie J. Miner(University of Michigan), Fengyun Su(University of Michigan), Subhendu Mukherjee(University of Debrecen), Ulka N. Vaishampayan(Wayne State University), Victoria Zhixuan Zeng(University of Michigan), Costas A. Lyssiotis(University of Michigan), Bilash Kuila(Aurigene Discovery Technologies (India)), Rui Wang(University of Michigan), Nam Hoon Kim(University of Michigan), Yang Zheng(Harbin Medical University), Caleb Cheng(University of Michigan), Lanbo Xiao(University of Michigan), Yuanyuan Qiao(University of Michigan)
Cited by 22
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k